Tag Archives: George E. Anastassov

Axim Biotech - MedChew Rx

AXIM Biotech Files Patent on Controlled Release Chewing Gum to Provide Opioid Addiction Treatment

AXIM Biotech Files Patent on Controlled Release Chewing Gum to Provide Opioid Addiction Treatment

NEW YORK, June 23, 2017 /Weed Wire/ — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469, a patent of invention that involves a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment.

Axim Biotech - MedChew Rx

AXIM Biotech Receives Schedule 1 Permit to Move Forward With Development of MedChew Rx Pharmaceutical Chewing Gum

NEW YORK, May 02, 2017 /Weed Wire/ — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company’s product development partner Quay Pharmaceuticals Ltd. (“Quay Pharma”) has obtained the relevant licenses from the British Home Office to import and work with the controlled drugs that are required to continue the development of AXIM’s MedChew Rx® pharmaceutical chewing gum’s family of products.

Axim Biotech - MedChew Rx

AXIM Biotech Enters IBS Clinical Trial for Canchew CBD Chewing Gum

NEW YORK, Jan. 18, 2017 /Weed Wire/ — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has entered clinical trials on treating irritable bowel syndrome (IBS) with the Company’s CanChew Plus® cannabidiol (CBD) gum at Wageningen University in the Netherlands.

bq7xic1ceaae77r-pnglarge

New U.S. Patent Allowance Granted to AXIM® Biotech for Use of All Cannabinoids in Its Controlled-Release Chewing Gum Products

NEW YORK, Nov. 16, 2016 /Weed Wire/ — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in hemp cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 9,433,601.


Top